Stocks · News reference
Envoy Medical completed three-month visits for all 56 patients in its Acclaim cochlear implant trial as it moves toward an FDA PMA submission.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Top Wall Street analysts changed outlook on top names. Baird raised PSN target, BTIG cut WMT target, HSBC raised TX target, Rothschild upgraded EFX, HC Wainwright lowered COCH target, BTIG cut MDXH target, Baird raised ROST target.
Read original at benzingaHC Wainwright & Co. analyst Yi Chen maintains Envoy Medical (NASDAQ:COCH) with a Buy and lowers the price target from $2.5 to $2.
Read original at benzinga-SEC Filing
Read original at benzingaEnvoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 78.13 percent increase over losses of $(0.32) per share from the
Read original at benzinga